The Stockholm Stock Exchange listing committee has approved CellaVision AB (publ) for listing on NASDAQ OMX Stockholm, Small Cap. First day of trading will be 31 May 2010.
The listing means that the trading in CellaVision shares is moved from the marketplace NASDAQ OMX First North Premier ("First North") to NASDAQ OMX Stockholm. First day of trading is 31 May 2010. The listing of CellaVision's share on First North thereby ceases and last day of trading on First North is on 28 May 2010. The Company's shareholders do not have to take any action in connection with the listing on NASDAQ OMX Stockholm. No issue of new shares is taking place in connection with the listing on NASDAQ OMX Stockholm. The share will be traded under the same ticker as before; CEVI, ISIN-code SE0000683484.
"Since our first year of revenue in 2001, CellaVision has demonstrated strong growth and rising profitability. The listing on NASDAQ OMX Stockholm is part of CellaVision's growth strategy and is made to facilitate for institutional investors to invest in the CellaVision share and creating prerequisites for improved liquidity in the share, which increases the flexibility in the Company's continued expansion. Furthermore, the listing is expected to bring increased attention from customers and partners, the stock market, media and other external stakeholders, thus increasing CellaVision's exposure." says Yvonne Mårtensson, CEO of CellaVision.
A prospectus (in Swedish only) is available at the company website; www.cellavision.com/prospekt. In the prospectus the following financial goals (not previously publicised) for CellaVision are included:
CellaVision's financial target is to grow its revenue with at least 15% per year, on average over a business cycle, with an operating margin exceeding 15%.
ABG Sundal Collier acted as financial advisor in connection with the listing process.
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB
Tel: +46 70 535 44 44, E-mail: lars.gatenbeck@lifeequity.se
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82, E-mail: yvonne.martensson@cellavision.se
Johan Wennerholm, CFO, CellaVision AB
Tel: +46 708 33 81 68, E-mail: johan.wennerholm@cellavision.se
About CellaVision
CellaVision AB (publ) develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in the US, Canada and Japan. For more information, please visit www.cellavision.com.